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Abstract
The lysosomal endoprotease legumain (asparaginyl endoprotease) has been proposed as a putative biomarker in prostate 
tumours, in which the enzyme is markedly overexpressed. Overexpression, coupled with highly selective specificity for 
cleavage of substrates at the C-terminus of asparagine (Asn) residues, make legumain an attractive biochemical target for 
potential diagnosis, prognosis and treatment. We report the design, synthesis, characterisation and preliminary evaluation 
of a new rhodamine-B (Rho-B)-labelled legumain peptide substrate probe 5 [Rho-Pro-Ala-Asn-PEG-AQ(4-OH)] and its 
selective targeting to lysosomes in PC3 prostate cancer cells. Probe 5 was efficiently activated by recombinant human legu-
main to afford the high quantum yield reporter fluorophore tripeptide 4b (Rho-Pro-Ala-Asn-OH) with concomitant release 
of intense fluorescence. Furthermore, probe 5 was activated upon incubation with homogenates derived from fresh-frozen 
tissue material of prostatectomy specimens. Probe 5 represents a new viable biochemical tool for probing the activity of 
legumain with the potential to be used in ex vivo diagnostics in the cancer pathology laboratory.
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Introduction
Prostate cancer (Pca) is one of the most prevalent cancers 
and its incidence is increasing in Western society (Siegel 
et  al. 2016). The early diagnosis of pre-invasive and 
metastatic tumour cells in patients is pivotal for the judi-
cious choice of treatment and success of therapies and for 
the improvement of survival rates. Early diagnosis of Pca 
is usually reliant on techniques that include digital rectal 
examination, magnetic resonance imaging and transrectal 
ultrasound-guided biopsy in conjunction with screening 
for serum levels of prostate specific antigen (PSA) which 
remains the principal biomarker for Pca (Zhang et al. 2017). 
A challenge across the spectrum of cancers is to identify and 
incorporate into clinical practice, well-defined and validated 
diagnostic and predictive biomarkers of disease (Dijkstra 
et al. 2012; Hemminki et al. 2012; Selvolini and Marrazza 
2017; Ueland 2017).
Despite its widespread use, the lack of tumour specific-
ity of PSA can lead to misdiagnosis and over diagnosis of 
low-risk Pca (Dijkstra et al. 2012). Such over diagnosis is 
a consequence particularly in the so-called ‘grey area’ of 
PSA levels between 4.0 and 10.0 ng/mL. Therefore, new 
biomarkers with ease of detection, increased sensitivity 
and specificity are required to advance diagnosis of Pca. 
Potential alternative biomarkers have been proposed and 
are the subject of recent review (Saini 2016), however, to 
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date no individual marker has replaced the routine focus 
on PSA.
Recent studies have highlighted that opportunities to 
exploit biomarker-drug co-development can aid the suc-
cessful application of molecular marker-based cancer 
therapies (Twomey et al. 2017). Novel markers includ-
ing those obtained from the blood or tumour tissue are 
being evaluated to provide either earlier or more accurate 
detection or prediction. Given that cancer development 
and metastasis depend on the function of many proteins, 
many metabolic enzymes and proteases provide biomarker 
candidates for cancer early detection (Wang et al. 2017). 
Tumour-associated proteases are targets for small molecu-
lar fluorescent imaging probes and fluorescent theranos-
tics. Progress in chemical probe design and fluorescence 
imaging is a rapidly developing area and the subject of 
recently published reviews (Garland et al. 2016; Gao et al. 
2017; Lee et al. 2018).
In this study, we focus on the cancer-associated pro-
tease and putative tissue biomarker legumain in prostate 
cancer. Legumain or asparaginyl endoprotease (AEP) 
[EC.3.4.22.34] has been proposed not only as a putative bio-
marker in prostate (Ohno et al. 2013), but breast (Gawenda 
et al. 2007; Liu et al. 2003), ovary (Wang et al. 2012) and 
colon (Haugen et al. 2015) cancers, in which the enzyme 
is markedly overexpressed. In colorectal cancer patients, 
reduced expression of legumain has been related with bet-
ter prognosis (Murthy et al. 2005).
Legumain is a unique lysosomal member of the clan CD 
(C13) protease family and is proteolytically active at acidic 
pH (4.5–5.0) and has selective substrate specificity of cleav-
age of amide bonds adjacent to C-termini of asparagine resi-
dues (Chen et al. 1997; Dall and Brandstetter 2013, 2016). 
The enzyme is synthesised as a zymogen (56 kDa) and the 
mechanisms of its lysosome-mediated processing via an 
intermediate 47 kDa form and a catalytically active 46 kDa 
form to the mature form of legumain (36 kDa) have been 
fully described (Dall and Brandstetter 2013, 2016). Further-
more, legumain has been reported to regulate the expression 
of other cancer-associated proteases including cathepsins B, 
H and L (Shirahama-Noda et al. 2003) and is involved in 
extracellular matrix turnover including conversion of met-
alloproteinase 2 (MMP2) zymogen into the active form of 
MMP2, a known contributor to cancer invasion and metas-
tasis, by proteolytic removal of an N-terminal propeptide 
(Chen et al. 2001). Although principally found in lysosomes 
and late endosomes (Chen et al. 1998), legumain is highly 
expressed by tumour associated macrophages (TAMs) (Luo 
et al. 2006) and colocalises with integrins at the invading 
edge of tumours which correlates with increased invasive-
ness (Gawenda et al. 2007; Lewis and Murdoch 2005; Liu 
et al. 2012; Shih et al. 2006; Wu et al. 2006). Legumain has 
recently been reported to be present in the nucleus and it is 
suggested that it may contribute to degradation of histones 
(Dall and Brandstetter 2016).
The prevalence of legumain in the tumour microenviron-
ment has prompted the design of a limited number of prod-
rugs for targeting its proteolytic activity (Liu et al. 2003; 
Luo et al. 2006; Smith et al. 2014; Stern et al. 2009). Also, 
studies of the functional imaging of legumain and other 
cysteine proteases in cancer have been undertaken using 
activity-based probes that function as covalent inhibitors in 
the active site of the enzyme (Edgington et al. 2011, 2013), 
as an alternative to the substrate approach adopted here. 
Increased expression in prostate cancer has been correlated 
with raised invasiveness and aggressiveness (Ohno et al. 
2013).
The overexpression of legumain in Pca, combined with 
its unique restricted substrate specificity makes legumain 
a smart candidate for tumour-specific detection and in this 
study have afforded the motivation to exploit these proper-
ties in the design of a novel diagnostic substrate probe that 
could be activated in the tumour microenvironment and to 
preliminarily evaluate its potential application as a support-
ive assay in the diagnosis of prostate acinar adenocarcinoma 
in prostate core biopsy and resection samples.
We report here the design, synthesis and characterisation 
of a novel intramolecularly quenched, fluorogenic legumain 
peptide substrate probe 5 [Rho-Pro-Ala-Asn-PEG-AQ(4-
OH)], its selective lysosomal targeting in live PC3 prostate 
cancer cells and activation in both recombinant human legu-
main and fresh-frozen tissue material from prostatectomy 
specimens.
Materials and Methods
Chemistry
Common solvents (including HPLC grade) were purchased 
from Fisher Scientific (Loughborough, UK) and used with-
out further purification. Aluminium plates (Kieselgel 60 
 F254 silica plates) were used for thin-layer chromatography 
(TLC) analysis. TLC solvent systems were as follows: (A) 
 CHCl3–MeOH (9:1, v/v), (B) n-BuOH–AcOH–H2O (4:5:1, 
v/v/v). Davisil Kieselgel LC60A 40–63 µm silica was used 
for column chromatography (Fisher Scientific; UK). Fmoc-
Asn (Trt)-NovaSyn®TGT and peptide derivatives Fmoc-Asn 
(Trt)-OH, Fmoc-Ala-OH, H-Pro-OtBu·HCl were purchased 
from  Novabiochem® Merck Millipore. All other reagents 
were obtained from Sigma-Aldrich Merck (Gillingham, UK) 
Purity of compounds was assessed as ≥ 95% by RP-HPLC on 
a Waters X-bridge Shield RP18 column (2.1 mm × 30 mm); 
flow rate 0.2 mL/min) using a one step linear gradient 
mobile phase A (100% ACN with 0.1% TFA and B  (H2O 
with 0.08% TFA (B). Ratios (A:B) were changed from 
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25:75 to 50:50 over 10 min; total run time 15 min; injec-
tion volume 10.0 µL; column temperature 25º C. 1H and 13C 
NMR spectra were recorded on either a Bruker AC300 or 
a Bruker AC400 NMR spectrometer at  25οC at 300.1 MHz 
and 75.47 MHz, respectively, from samples dissolved either 
in deuterated DMSO or deuterated chloroform. In 13C, a 
DEPT (Distortionless Enhancement by Polarization Trans-
fer) experiment was conducted to differentiate between qua-
ternary, methylene carbons, methine and methyl carbons. 
High resolution mass spectra with electrospray ionization 
(HRMS-ESI) were recorded using a ThermoFisher LTQ 
Orbitrap XL or a Waters ZQ4000 instrument. UV–vis spec-
tra were measured on a Beckman DU800 spectrophotom-
eter; scan speed 1200 nm/min and wavelength range 400 to 
800 nm. Full characterisation data for all new compounds, 
including 1H and 13C NMR spectra; UV/visible absorption 
spectra; and HPLC characterisation chromatograms are pre-
sented in the accompanying Supplementary Information file 
Sections 1, 3–7 and 9).
Abbreviations: AEP, asparaginyl endoprotease; AMC, 
7-amino-4-methylcoumarin; AQ, anthraquinone; Boc, tert-
butoxycarbonyl;  Boc2O, di-tert-butyl dicarbonate; CBZ, 
benzyloxycarbonyl; DCM, dichloromethane; DIPEA, N,N-
diisopropylethylamine; DMF, N,N-dimethylformamide; 
FRET, fluorescence resonance energy transfer; HOBt, 
1-hydroxybenzotriazole; MES, 2-(N-morpholino)ethane-
sulfonic acid; MMP, matrix metalloproteinase; MTT, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide; PEG, polyethyleneglycol; PyBop, benzotriazole-
1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate; 
PyClock, 6-chloro-benzotriazole-1-yloxy-tris-pyrrolidi-
nophosphonium hexafluorophosphate; Rho, rhodamine; 
TAM, tumour associated macrophage; TBTU, 2-(1H-benzo-
triazole-1-yl)-1,1,3,3,-tetramethylaminium tetrafluoroborate; 
TFA, trifluoroacetic acid; Trt, triphenylmethyl (trityl).
Experimental Synthesis Protocols
( 2‑{ 2‑[ 2‑( 4‑H ydr oxy ‑9, 10‑ dio xo‑ 9,1 0‑d ihy dro ‑an thr ace n‑1 
‑yl ami no) ‑et hox y]‑ethoxy}‑ethyl)‑carbamic Acid Tert‑butyl 
Ester (2)
To a solution of leucoquinizarin 1 (1 g, 4.1 mmol) in DCM 
(10  mL) was added 2,2′-(ethylenedioxy)bis(ethylamine) 
(2.4 mL, 16.4 mmol) and the reaction mixture was refluxed 
for 1 h.  Et3N (100 µL) was added and the solution was aer-
ated at rt. After 2 h, the solvent was evaporated in vacuo and 
the crude 1-{2-[2-(2-aminoethoxy)-ethoxy]ethylamino}-
4-hydroxy-anthracene-9,10-dione was dissolved in MeOH 
(2.5 mL).  Boc2O (3.6 g, 16.5 mmol) in MeOH (4 mL) was 
added dropwise and the mixture was stirred at 0 °C for 2 h. 
The solvent was evaporated and the residue was dissolved in 
 CHCl3 (100 mL). The organic layer was washed with water 
(3 × 100 mL), dried over anhydrous  Na2SO4, filtered and 
concentrated in vacuo and purified by silica-gel column chro-
matography  [CHCl3 and EtOAc (4:1) plus MeOH (1–10%)]. 
The fractions containing the major product were combined, 
filtered, evaporated in vacuo to dryness to give compound 2 
as a purple solid (0.82 g, 42%). Rf 0.5 (solvent B). 1H NMR 
 (CDCl3, 300 MHz): δ (ppm) 1.41 [s, 9H, C(CH3)3], 3.36 (m, 
2H, CH2–NHCO), 3.55 (m, 4H, CH2–O–CH2–CH2–O–CH2–), 
3.70 (m, 4H, –O–CH2–CH2–O–), 3.78 (t, 2H, Aq-NH–CH2), 
5.28 (s, 1H, NHCO), 7.14 (m, 2H), 7.70 (m, 2H), 8.24 (m, 2H), 
10.30, (t, 1H, Aq-NH, J = 6 Hz) 13.59 (s, 1H, OH). 13C NMR 
 (CDCl3,75.5 MHz): δ (ppm) 28.4 (C(CH3)3), 40.5  (CH2), 
42.6  (CH2), 69.6  (CH2–O), 70.2  (CH2–O), 70.4  (CH2–O), 
70.7  (CH2–O), 79.0 C(CH3)3, 108.6  (CAR), 113.6  (CAR), 
123.8  (CHAR), 126.2  (CHAR), 126.7  (CHAR), 128.6  (CHAR), 
132.4  (CHAR), 132.5  (CAR), 134.0  (CHAR), 135.2  (CAR), 
147.3  (CAR), 156.0  (CAR), 156.6 (C=O, Boc), 181.9 (C=O, 
Aq), 187.3 (C=O, Aq). HRMS (ESI) m/z: [M + H]+ Calcd for 
 [C25H31N2O7]+ 471.2126; Found 471.2117.
2‑{2‑[2‑(4‑Hydroxy‑9,10‑dioxo‑9,10‑dihydro‑anthra‑
cen‑1‑ylamino)‑ethoxy]‑ethoxy}‑ethylammonium Trifluoro‑
acetate (3)
Compound 2 (0.8 g, 1.69 mmol) was dissolved in TFA 
(2 mL) at rt. After 30 min, the solvent was evaporated and 
the residual solid re-evaporated with ethanol (3 × 10 mL) 
before dissolving in a minimum volume of ethanol (3 mL). 
Addition of ether (100 mL) gave a precipitate of the depro-
tected anthraquinone spacer-linked amino acid conjugate 
as the N-terminal trifluoroacetate salt 3 which was filtered 
off and dried in vacuo (0.6 g, 95%). Rf 0.4 (solvent B). 
RP-HPLC tR 4.2 min. 1H NMR (DMSO-d6, 300 MHz): δ 
(ppm) 3.02 (t, 2H, CH2–NH3+), 3.52 (m, 2H, Aq-NH–CH2), 
3.68 (m, 8H, CH2–O–CH2–CH2–O–CH2–), 7.21 (d, 1H, 
J = 9 Hz), 7.37 (d, 1H, J = 9 Hz), 7.81 (m, 2H), 8.00 (s, 3H, 
NH3+), 8.11 (m, 2H), 10.21, (t, 1H, Aq-NH), 13.54 (s, 1H, 
OH). 13C NMR (DMSO-d6, 75.5 MHz): δ (ppm) 38.9  (CH2), 
42.0  (CH2), 66.7  (CH2–O), 68.9  (CH2–O), 69.6  (CH2–O), 
69.6  (CH2–O), 107.2  (CAR), 112.7  (CAR), 115.2  (CAR), 119.2 
 (CAR), 125.3  (CHAR), 125.8  (CHAR), 126.2  (CHAR), 128.4 
 (CHAR), 131.7 (COOH), 132.7  (CHAR), 134.4  (CHAR), 147.0 
 (CAR), 156.0  (CAR), 158.1 to 158.5 (q, CF3), 180.6 (C=O, 
Aq), 186.5 (C=O, Aq). HRMS (ESI) m/z: [M-C2O2F3]+ 
Calcd for  [C20H23N2O5]+ 371.1601; Found 371.1598.
{9‑[2‑(2‑{1‑[1‑Carboxy‑2‑(trityl‑carbamoyl)‑ethylcarbamoyl
]‑ethylcarbamoyl}‑pyrrolidine‑1‑carbonyl)‑phenyl]‑6‑dieth‑
ylamino‑xanthen‑3‑ylidene}‑diethylammonium Trifluoro‑
acetate (4a)
Fmoc-Asn(Trt)-NovaSyn®TGT (1.0 g) resin was swelled 
with DCM for 1  h. The resin-bound Fmoc-protected 
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peptide was treated with 20% (v/v) piperidine in DMF 
(2 × 10 mL) for 15 min (2×) followed by washing with 
DMF (3×). A solution of Fmoc-Xaa-OH (2 eq), TBTU 
(1.9 eq), HOBt (1.9 eq), DIPEA (4 eq.) in DMF (8–10 mL) 
was added to the resin bound free amine peptide and 
shaken for 1  h at rt. The resin-bound Fmoc-protected 
peptide was treated with 20% piperidine in DMF (v/v) 
for 15 min (2×). The resin was washed with DMF (3×). 
A solution of Rho-B (0.22 g, 1.5 eq.), Pyclock (0.25 g, 
1.5 eq.), DIPEA (0.15 mL, 3 eq) in DMF (4 mL) was 
added and shaken for 1 h. The coupling was repeated 
another times and the resin was washed with DMF (3×). 
The resin was washed with DCM (10×) and cleaved from 
the resin by repeated treatment with a cleavage solution 
of 0.5% TFA in 100 mL DCM for 1 h. The combined, 
filtered extracts were evaporated in vacuo to dryness and 
the resulting residue was triturated with ether to give com-
pound 4a as a pink solid (0.29 g). Rf 0.5 (solvent B). RP-
HPLC tR 11.2 min.
1H NMR (DMSO-d6, 300 MHz): δ (ppm) 1.06 (d, 3H, 
CH3-Ala, J = 6 Hz), 1.14 (t, 12H, 4 × CH3-Rho, J = 6.9 Hz), 
1.52 (m, 1H, β-CH-Pro), 1.72 (m, 2H, γ-CH2-Pro); 1.97 (m, 
1H, β-CH′-Pro), 2.49 (β-CH2-Asn, obscured by solvent), 
2.99 (q, 8H, 4 × CH2-N-Rho), 3.47 (m, 2H, δ-CH2-Pro), 
4.09 (t, 1H, α-CH-Pro), 4.28 (m, 1H, α-CH-Asn), 4.45 (m, 
1H, α-CH-Ala), 6.94 (d, 2H, H-4, 5, J = 3 Hz); 7.09–7.32 
[m, unresolved, 19H (H-1, 2, 7, 8 and Trt)], 7.53 (m, 1H, 
H-6′), 7.75 (s, 1H, NHCO), 7.77 (m, 3H, H-3′, 4′, 5′), 7.85 
(d, 1H, NHCO), 7.91 (d, 1H, NHCO). HRMS (ESI) m/z: 
[M-C2O2F3]+ Calcd for  [C59H63N6O7]+ 967.4753; Found 
967.4747.
[9‑(2‑{2‑[1‑(2‑Carbamoyl‑1‑car‑
boxy‑ethylcarbamoyl)‑ethylcarbamoyl]‑pyrrol‑
idine‑1‑carbonyl}‑phenyl)‑6‑diethylamino‑xan‑
then‑3‑ylidene]‑diethylammonium Trifluoroacetate (4b)
Compound 4a (0.1 g, 92.5 mmol) was dissolved in TFA 
(3 mL). After 3 h, the solution was evaporated in vacuo and 
the residue triturated with diethyl ether to give compound 
4b as a pink solid (0.069 g, 89%). Rf 0.53 (solvent A). RP-
HPLC tR 4.60 min.
1H NMR (DMSO-d6, 300 MHz): δ (ppm) 1.05 (d, 3H, 
CH3-Ala, J = 6 Hz), 1.22 (t, 12H, 4 × CH3-Rho, J = 6.9 Hz), 
1.57 (m, 1H, β-CH-Pro), 1.80 (m, 2H, γ-CH2-Pro); 1.96 (m, 
1H, β-CH′-Pro), 2.42 (β-CH2-Asn), 3.55 (m, 2H, δ-CH2-
Pro), 3.66 (q, 8H, 4 × CH2-N-Rho), 4.05 (m, 1H, α-CH-Pro), 
4.23 (m, 1H, α-CH-Asn), 4.38 (m, 1H, α-CH-Ala), 6.94 (d, 
2H, H-4, 5, J = 3 Hz); 7.14 (m, 4H, H-1, 2, 7, 8), 7.52 (m, 
1H, H-6′), 7.75 (s, 1H, NHCO), 7.77 (m, 3H, H-3′, 4′, 5′), 
7.90 (d, 1H, NHCO). HRMS (ESI) m/z: [M-C2O2F3]+ Calcd 
for  [C40H49N6O7]+ 725.3657; Found 725.3653.
{9‑[2‑(2‑{1‑[2‑Carbamoyl‑1‑(2‑{2‑[2‑(4‑hydroxy‑9,10‑di‑
oxo‑9,10‑dihydro‑anthracen‑1‑ylamino)‑ethoxy]‑ethoxy}
‑ethylcarbamoyl)‑ethylcarbamoyl]‑ethylcarbamoyl}‑pyr‑
rolidine‑1‑carbonyl)‑phenyl]‑6‑diethylamino‑xan‑
then‑3‑ylidene}‑diethylammonium Trifluoroacetate (5)
To a solution of compound 3 (0.1 g, 0.20 mmol) in DMF 
(2 mL) was added compound 4a (0.18 g, 0.18 mmol) in the 
presence of PyBOP (0.161 g, 0.30 mmol), HOBt (0.042 g, 
0.31 mmol) and DIPEA (0.165 mL, 0.93 mmol) in DMF 
(4 mL) and at rt. After 2 h, the organic layer was washed 
with water (3 × 100 mL), dried over anhydrous  Na2SO4, 
filtered and concentrated in vacuo and purified by silica-
gel column chromatography  [CHCl3 and EtOAc (4:1) 
plus MeOH (1–10%)]. The fractions containing the major 
product were combined, filtered, evaporated in vacuo to 
dryness. The residue was treated with TFA (1 mL) for 
3 h. The solution was evaporated in vacuo to dryness. The 
residue was triturated with ether to give compound 5 as a 
purple solid (0.1 g, 31.2%). Rf 0.5 (solvent A). RP-HPLC 
tR 5.2 min.
1H NMR (DMSO-d6, 300  MHz): δ (ppm) 1.07 (d, 
3H, CH3-Ala, J = 6  Hz), 1.20 (t, 12H, 4 × CH3-Rho, 
J = 6.9 Hz), 1.55 (m, 1H, β-CH-Pro), 1.65 (m, 2H, γ-CH2-
Pro), 1.95 (m, 1H, β-CH′-Pro), 2.41 (d, 2H, β-CH2-Asn, 
J = 6  Hz), 3.12 (m, 2H, CH2–NHCO) 3.32–3.75 (m, 
20H, δ-CH2-Pro, CH2–O–CH2–CH2–O–CH2, 4 × CH2-
N-Rho, Aq-NH–CH2), 3.80–3.99 (m, 2H, α-CH-Pro, 
α-CH-Asn), 4.32 (m, 1H, α-CH-Ala), 6.87 (d, 2H, H-4, 
5, Rho, J = 3 Hz), 7.08 (m, 4H, H-1, 2, 7, 8, Rho), 7.32 
(m, 1H, H-2, Aq), 7.51 (d, 2H, H-3, Aq; H-6′, Rho), 7.65 
(s, 1H, NHCO), 7.76 (3H, H-3′, H-4′, H-5′), 7.83 (s, 1H, 
NHCO), 7.86 (m, 2H, H-6, 7, Aq), 8.19 (d, 1H, NHCO), 
8.22 (m, 2H, H-5, -8, Aq), 10.35 (t, 1H, Ar–NH), 13.57 
(s, 1H, OH). 13C NMR (DMSO-d6, 75.5 MHz): δ (ppm) 
12.4 (4 × CH3-Rho), 17.2  (CH3-Ala), 25.1 (γ-CH2-Pro), 
29.0 (β-CH2-Pro), 38.6 (β-CH2-Asn, obscured by solvent), 
40.3  (CH2-N, obscured by solvent), 42.1  (CH2-N), 45.3 
 (CH2-N), 48.7 (α-CH), 49.5 (α-CH), 49.8  (CH2-N), 58.9 
(α-CH), 68.8  (CH2–O), 68.0  (CH2–O), 69.6  (CH2–O), 
69.7  (CH2–O), 95.7  [CHAR (C-4,-5, Rho)], 107.3  (CAR), 
112.6  (CAR), 112.8  (CAR), 113.3  (CAR), 113.8  (CHAR), 
114.2  (CHAR), 125.7  (CHAR), 125.9  (CHAR), 126.3 
 (CHAR), 127.3  (CHAR), 128.6  (CHAR), 129.8  (CHAR), 
130.2  (CHAR), 130.3  (CAR), 131.0  (CHAR), 131.8  (CHAR), 
132.9  (CHAR), 134.7  (CHAR), 136.5  (CAR), 147.3  (CAR), 
154.9  (CAR), 155.0  (CAR), 155.9  (CAR), 156.1  (CAR), 157.0 
 (CAR), 157.2  (CAR), 166.0  (CAR), 170.6 (NHCO), 170.7 
(NHCO), 171.4 (NHCO), 171.6 (NHCO), 171.7 (NHCO), 
180.7 (C=O, Aq), 186.7 (C=O, Aq). HRMS (ESI) m/z: 
[M-C2O2F3]+ Calcd for 1077.5080  [C60H69N8O11]+; Found 
1077.5065.
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[9‑(2‑{2‑[1‑(2‑Carbamoyl‑1‑car‑
boxy‑ethylcarbamoyl)‑ethylcarbamoyl]‑ethyl‑
carbamoyl}‑phenyl)‑6‑diethylamino‑xan‑
then‑3‑ylidene]‑diethylammonium Trifluoroacetate (6)
Compound 6 was synthesised by directly analogous pro-
cedures to those for compounds 4a and 4b, using Fmoc-
Asn(Trt)-NovaSyn®TGT resin (1.0  g), as a pink solid 
(0.152 g; 74%). Rf 0.4 (solvent A). RP-HPLC tR 4.08 min. 
1H NMR (DMSO-d6, 300 MHz): δ (ppm) 1.08–1.21(m, 
unresolved, 15H, CH3-Ala, 4 × CH3-Rho), 2.10 (m, 2H, 
CH2–CONH), 2.49 (d, 2H, β-CH2-Asn), 3.18 (t, 2H, 
 CH2–NHCO, J = 6.9 Hz), 3.37 (q, 8H, 4 × CH2-N-Rho), 4.17 
(m, 1H, α-CH-Asn), 4.45 (m, 1H, α-CH-Ala), 6.29–6.45 
(m, 5H, unresolved, H-2, 4, 5, 7 and NHCO), 6.87 (s, 1H, 
NHCO), 6.90 (d, 1H, H-6′), 7.34 (s, 1H, NHCO), 7.49 
(m, 2H, H-1, 8), 7.78 (m, 1H, H-4′), 8.02 (t, 2H, H-3′, 
5′). HRMS (ESI) m/z: [M-C2O2F3]+ Calcd for 657.1838 
 [C33H29N8O11]+; Found 657.1824.
Rho‑Pro‑Ala‑Ala‑PEG‑AQ(4‑OH) (7)
Compound 7 (control peptide) was synthesised by an analo-
gous procedure to that used for probe 5, described above, 
except alanine (Ala) was substituted for Asparagine (Asn) 
in the peptide sequence. To a solution of compound H-Pro-
Ala-Ala-PEG-AQ(4-OH) (0.2 g, 0.27 mmol) in DMF (3 mL) 
was added Rho-B (0.16 g, 0.33 mmol), PyBOP (0.172 g, 
0.33  mmol), HOBt (0.04  g, 0.32  mmol) and DIPEA 
(0.22 mL, 1.2 mmol) in DMF (4 mL) at rt to give 7 (fol-
lowing method A) as a purple solid (0.1 g, 32%). Rf 0.4 
(Solvent System B). HRMS (ESI) m/z: [M-C2O2F3]+ Calcd 
for 1034.5022  [C59H68N7O10]+; Found 1034.5021.
Fluorescence Studies: pH Dependence of Fluores‑
cence of Rhodamine‑Labelled Tripeptides 4b and 6
Fluorescence emission spectra were measured on a Per-
kin Elmer LS50B luminescence spectrometer; scan speed 
500 nm/min, λex 562 nm, λem 570–700 nm, excitation slit 
and emission slit widths were 4.5 nm and 5.5 nm, respec-
tively. For the experiments, compounds 4b and 6 were mixed 
with Mcllvaine assay buffer (McIlvaine 1921) to produce a 
final concentration in a quartz cuvette (3 mL) of 10 μM and 
40 μM, respectively, across pH 3–8 range.
Determination of Relative Fluorescence Quantum 
Yields
N-Rhodamine labelled tripeptides 4b and 6 and the reference 
standard rhodamine B were prepared as stock solutions (1 mg/
mL) in ethanol. The absorbance spectra (see Supplementary 
Information file) of the compounds in ethanol (pH 5) were 
recorded on a Beckman DU800 spectrophotometer with a 
scan speed 1200 nm/min and wavelength range 400 to 800 nm 
in 1 cm path length quartz cuvettes. The Beer–Lambert law 
(A = εcl) was used to determine the extinction coefficients of 
test samples. Extinction coefficients were determined at λmax. 
Fluorescence emission spectra were recorded by diluting the 
reference standard and test samples x 10 in ethanol, scan speed 
500 nm/min; λex 535 nm, λem 540–700 nm; excitation slit and 
emission slit widths were 4.5 nm and 5.5 nm. The quantum 
yield was calculated using the following equation:
where m is the slope of the line obtained from the plot of the 
integrated fluorescence versus absorbance; n is the refrac-
tive index of the solvent and subscript R refers to the refer-
ence fluorophore of known quantum yield (rhodamine B, 
Φ = 0.73 ± 0.02) (Rurack 2008). Given that ethanol was used 
as the solvent for the reference and each of compounds 4b 
and 6, the term (n2∕n2
R
)
= 1.
Activation of Probe 5 by Recombinant Human Legu‑
main in Vitro
Human recombinant legumain was obtained from R&D Sys-
tems (Abingdon, UK). A FLUOstar Omega multi-mode micro-
plate reader (BMG Labtech, Ortenberg, Germany) was used 
to measure fluorescence. Stock solutions of probe 5 and fluo-
rophore 4b were prepared at 1 mg/mL in DMSO. Legumain 
activation and assay buffers were prepared as follows: activa-
tion buffer (50 mM sodium acetate, 100 mM NaCl, pH 4.0); 
assay buffer [50 mM MES hydrate (Sigma) 250 mM NaCl, pH 
5.0]. Recombinant human legumain (10.0 µg) was diluted with 
activation buffer (100 µL, pH 4.0) and frozen at − 80 °C. An 
aliquot (476.2 ng per 5 µL) of de-frosted foregoing solution 
was incubated at 37 °C for 2 h, followed by dilution with assay 
buffer to 1 ng/μL. The final concentrations of compounds 5 
and 4b were each 10 µM in total reaction volumes of 100 µL 
in assay buffer (pH 5.0) either with or without rh-legumain 
(40.0 ng). Fluorescence of probe 5 was measured using a 
microplate reader (λex—540 nm; λem—590 nm) at 37 °C for 
2 h using F16 black maxisorp 96 well plates. The continuous 
increase in fluorescence intensity was monitored by repeated 
measurements as a measure of enzyme-mediated probe activa-
tion. Mean relative fluorescence intensity was plotted against 
time with subtraction of background fluorescence.
Substrate Kinetic Assay
Pre-activated rh-legumain was added to legumain assay 
buffer (final volume 100 μL) with substrate probe 5 at 
concentrations ranging from 1 to 40 μM in a 96-well plate 
훷F = 훷R
[
m
mR
][
n2
nR
]
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(n = 3) at a final legumain concentration of 0.4  ng/μL. 
Hydrolysis of substrate probe 5 was monitored fluorimetri-
cally (λex 540 nm; λem 590 nm, based on the fluorescence 
properties of cleavage product and reporter fluorophore 4b) 
using a microplate reader at 2 min intervals at 37 °C for 2 h. 
Relative fluorescence intensity data of substrate probe 5 was 
processed by using enzyme kinetics wizard in SigmaPlot 12 
software to fit the data to a non-linear regression curve. Km 
was determined using a Michaelis–Menten plot of initial 
enzyme velocity versus substrate concentration. Km ± 1.5 μM 
for probe 5 (activated by rh-legumain).
Distribution Coefficient Assay
The distribution coefficient of compounds 3, 5 and 4b was 
determined by the ‘shake-flask’ method (Leo et al. 1971). 
PBS (0.01 M phosphate buffer; 0.0027 M potassium chlo-
ride; 0.137 M sodium chloride) and 1-octanol were from 
Sigma-Aldrich Merck (Gillingham, UK). Compounds 
(1 mg) were suspended in PBS buffer (pre-saturated for 24 h 
with 1-octanol) (900 µL) and 1-octanol (pre-saturated for 
24 h with PBS buffer) (900 µL), mixed by vortex and shaken 
at rt for 24 h to allow the compound to partition between the 
two phases. The layers were separated by centrifugation at 
2000 g for 5 min and the concentration in each phase was 
determined from calibration curves of absorbance versus 
concentration. The experiments were performed in triplicate. 
The distribution coefficients were calculated according to the 
following equation:
Cell Culture
PC-3 prostate cancer cells were obtained from the American 
Type Culture Collection (ATCC). PC-3 cells were grown in 
T75 tissue culture flasks using RPMI 1640 medium (Gibco; 
ThermoFisher Scientific) supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (Sigma-
Aldrich Merck, Gillingham, UK) in a humidified incubator 
(5%  CO2, 95% air) at 37 °C.
In Vitro Chemosensitivity Assay
Cell viability was determined by an MTT-based method 
(Plumb et al. 1989). MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H tetrazolium bromide] was obtained from 
Sigma-Aldrich Merck (Gillingham, UK). Briefly, PC-3 cells 
in exponential growth phase were seeded in 96-well plates 
to achieve a final density of 3 × 104 cells per well. After 
24 h incubation at 37 °C (5%  CO2, 95% air), the cells were 
log D = log
[ [
compound in organic phase
]
[
compound in aqueous phase
]
]
treated with final drug concentrations ranging from 100 to 
0.01μM. Following 96 h continuous exposure to drug at 
37 °C, cells were incubated with fresh drug-free medium 
immediately prior to addition of MTT solution (5 mg/mL 
in PBS). Medium and MTT were removed after 4 h and 
DMSO (150 μL) was added. The absorbance was measured 
at 550 nm, using a Labsystem Multiskan microplate reader. 
 IC50 values were obtained from growth curves of drug con-
centration against  % survival, using SigmaPlot 12 software, 
and are expressed in μM.
Confocal Microscopy Studies in PC3 Prostate Cancer 
Cells
For live cell imaging, PC-3 cells (1.5 × 105) were seeded in 
a 35 mm glass bottomed micro well dish (Ibidi/Thistle Sci-
entific, Glasgow, UK) and cultured for 24 h. For lysosome 
co-staining, cells were washed x 3 with PBS. LysoTracker 
Green DND 26 [(60 nM) Invitrogen, Paisley, UK] was 
added to the cell culture medium and incubated at 37 °C 
for 30 min prior to addition of probe 5 (1 µM) and imaging. 
For mitochondria co-staining, cells were washed x 3 with 
PBS, MitoTracker Green FM [(50 nM) Invitrogen, Paisley, 
UK] was added to the cell culture medium and incubated 
at 37 °C for 30 min prior to addition of probe 5 (1 µM) and 
imaging. Cells were imaged using a Zeiss LSM800 confo-
cal laser scanning microscope with a HCX PL APO lambda 
blue 63.0 × 1.4 oil objective, using Diode (405 nm), Argon 
(458, 488, 514 nm), HeNe (543 nm), HeNe (594 nm) and 
HeNe (633 nm) lasers. Image analyses were performed using 
Image J software.
Fresh‑Frozen Tissue Material
Fresh-frozen tissue curls were prepared during diagnostic 
frozen section sampling of 2 fresh prostatectomy specimens. 
Frozen curls were collected in sterile Eppendorf tubes indi-
vidually per each frozen section. Tubes were transferred 
immediately from − 20  °C into − 80  °C. Haematoxylin 
and eosin (H & E) frozen section slides were examined by 
pathologists to confirm that the section from the first speci-
men (PO1) contained benign prostatic tissue which showed 
no evidence of malignancy, whereas the section from the 
second specimen (PO2) contained a small foci of prostatic 
adenocarcinoma.
Both prostatectomy specimens were processed into for-
malin-fixed paraffin embedded tissue sections for diagnostic 
histological examination; H & E slides were examined by 
pathologists. On histological examination, sections from the 
first specimen (PO1) of the prostate showed a 3 mm focus 
of Gleason grade 3 + 3 = 6, adenocarcinoma in the right 
lobe more towards the apical side. There were foci of high 
grade PIN in adjacent slices. No other tumour was identified 
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elsewhere. The tumour replaced < 1% of the prostatic tissue. 
Background prostate showed nodular and numerous foci of 
stromal hyperplasia. Mild chronic inflammation was also 
present.
Sections from the second prostatectomy specimen (PO2) 
showed bilateral multifocal prostatic adenocarcinoma of aci-
nar type. The tumour was present as two large and two small 
nodules, the larger nodules measured 1.5 × 1 cm, which 
showed Gleason grade of 3 + 4 = 7 (95:5). The tumour 
replaced approximately up to 5% of the prostate volume. 
There were foci of high grade PIN and there was diffuse 
perineural invasion. There was no definite evidence of extra 
prostatic extension and no involvement of seminal vesicle or 
vas by the tumour. The background prostate showed nodular 
hyperplasia and mild chronic inflammation.
PO1 specimen was from a 71 y old male with raised 
PSA—5.2, DRE—Benign, and Radiological progression.
PO2 specimen was from a 52 y old male with raised PSA 
4.2, DRE—Benign, and Radiological progression.
Fresh‑Frozen Tissue Assay
Materials: Assay buffer [50 mM MES hydrate (Sigma) 
250 mM NaCl, pH 5.0]. Test compounds: legumain sub-
strate probe 5 (10 µM) and negative control, legumain non-
substrate peptide 7 (10 µM); iodoacetamide (protease inhibi-
tor, Sigma) (1 mM); F16 black maxisorp 96 well plates. 
Fluorescence was measured using a Perkin Elmer Enspire 
Multimode plate reader (λex 540 nm; λem 590 nm).
Method: fresh-frozen prostate tissue curls kept in the 
freezer were removed and placed on ice, weighed (60 mg 
sample mass) and added to the assay buffer at pH 5.0. 
Tissues were homogenised using a precooled spatula 
and blended in Eppendorf tubes on ice (4 ºC). Following 
homogenisation, the tissue preparation was centrifuged for 
15 min at 10,000 g. The supernatant was removed and used 
to incubate test compounds (96 well plates); the incubates 
were shaken for 5 min prior to recording the fluorescence 
emission spectra. Relative fluorescence intensity was moni-
tored for a period of 210 min at 37 ºC. Preincubation of 
homogenates with iodoacetamide (1 mM for 15 min) prior 
to addition of test compound(s) was performed to abrogate 
protease activity. Mean relative fluorescence intensity was 
plotted against time, with subtraction of (any) background 
fluorescence.
Results and Discussion
Probe Design
Biomolecular applications of fluorogenic molecular probes 
demand design features that permit selective activation, 
a substantial increase in emission intensity upon reac-
tion with the target protease, efficiency and stability. A 
fluorescence resonance energy transfer (FRET) system 
was designed to provide for continuous reaction monitor-
ing and rapid determination of enzyme activity and that 
could be envisaged as a potential simple tool for use in 
the cancer pathology laboratory, requiring inexpensive 
instrumentation; notably, to detect legumain biomarker 
activity in prostate tissue samples. The design of probe 
5 [Rho-Pro-Ala-Asn-PEG-AQ(4-OH)] (Fig. 1) as a new 
FRET peptide substrate of legumain, incorporating a rho-
damine B derivative modified at the 2´-carboxylic acid 
group was selected on the basis of its favourable photo-
stability, high relative fluorescence quantum yield, long 
emission wavelength, low cost and ease of access by 
chemical synthesis. The rhodamine donor fluorophore was 
demonstrated to be part of an efficient FRET pair with 
a novel PEG-spaced 1-amino-4-hydroxyanthraquinone 
derivative; the latter quencher (acceptor) was selected on 
the prediction that its absorption spectrum would signifi-
cantly overlap the emission spectrum of the fluorophore, 
thereby functioning as an effective ‘black hole’ quencher, 
effectively conferring no background fluorescence. Related 
1,4-diaminoanthraquinones are non-fluorescent quenchers 
with applications that include real-time PCR (Jernigan and 
Lawrence 2013; May et al. 2005). For strong recognition 
by legumain, the substrate probe 5 satisfied the stringent 
requirement for Asn in the P1 position; whereas Pro was 
selected in the P3 position based on a previously intimated 
best fit in an activity based probe (Sexton et al. 2007). 
Furthermore, coupling rhodamine B to the N-terminus of 
Pro ensured that the fluorophore was ‘locked’ into a ring-
opened form by tertiary amide formation, thereby prevent-
ing cyclisation to non-fluorescent lactam forms, analogous 
to the properties of piperazine derivatives of Rho-B (Beija 
et al. 2009). Inclusion of a short PEG- or polyethyleneg-
lycol-like linker, between the C-terminus of Asn and the 
amino-hydroxyanthraquinone quencher, enhanced aqueous 
solubility and could substitute for a P1′ amino acid resi-
due. Upon activation by legumain, the probe 5 was cleaved 
at the C-terminal side of the key Asn residue to release 
the strongly fluorescent tripeptide reporter fluorophore 4b 
(Rho-Pro-Ala-Asn-OH). Control compounds 7 and 6 were 
synthesised to complement the probe 5 and its fluorophore 
product 4b, respectively. Tripeptide 6 (which contained 
β-Ala in place of Pro) was prepared to affirm that it was 
important to retain the secondary amino acid Pro adjacent 
to the rhodamine label for efficient fluorescence and stabil-
ity. Compound 7, the quenched analogue of probe 5 was 
prepared as a negative control peptide for legumain activa-
tion (containing P1-Ala in place of the key Asn residue) 
given the absence of a cleavage ‘hotspot’.
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Synthesis
Figure 1 shows the synthetic procedures for the prepara-
tion of the novel legumain-activatable, FRET probe 5, its 
quencher moiety and associated rhodamine labelled trip-
eptides. The fluorogenic legumain substrate 5 was synthe-
sised by a convergent method. Controlled mono-amination 
(Kikuchi et al. 1982) of leucoquinizarin 1 with 2,2′-(ethylen-
edioxy)bis(ethylamine) in DCM, followed by air oxidation of 
the intermediate leuco-form of the product in the presence of 
 Et3N afforded 2-{2-[2-(4-hydroxy-9,10-dioxo-9,10-dihydro-
anthracen-1-ylamino)-ethoxy]-ethoxy}-ethyl-ammonium in 
its crude form. Facile chromatographic purification of the 
latter was achieved by temporary protection of the primary 
amino group using  Boc2O in MeOH to afford compound 2. 
Treatment of compound 2 with TFA afforded the stable, con-
veniently stored amine trifluoroacetate salt 3. The rhodamine 
B-labelled tripeptide Rho-Pro-Ala-Asn(Trt)-OH, 4a was 
synthesised on Fmoc-Asn(Trt)-NovaSyn®TGT resin. The 
coupling reactions were performed with a twofold molar 
excess of Fmoc-Ala-OH and Fmoc-Pro-OH, consecutively, 
using a 1.9-fold molar excess of activating agents (TBTU/
HOBt) in the presence of DIPEA in DMF. Attachment of 
the rhodamine B fluorophore was achieved via PyClock/
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Fig. 1  Synthesis of the Fluorogenic Legumain Peptide Substrate 
probe 5a. aa 2,2′-(Ethylenedioxy)bis(ethylamine), DCM, 40 °C, 1 h; b 
 Boc2O 20%, MeOH, 0 °C 2 h. c TFA, RT, 30 min. d PyBOP, HOBt, 
DIPEA, DMF, rt, 2 h. e TFA, rt, 2 h. Compounds 4a, 4b and 6 were 
synthesised by solid phase peptide synthesis. Compound 7 [Rho-Pro-
Ala-Asn-PEG-AQ(4-OH)] (negative control peptide) was synthesised 
by an analogous procedure to that used for probe 5, described above, 
except Ala was substituted for Asn at P1 in the peptide sequence
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DIPEA-mediated coupling on resin. The resin-bound, 
N-labelled, Asn-protected tripeptide was cleaved with TFA 
in DCM (0.5%) at room temperature to afford compound 
4a. Subsequently, the fluorescent tripeptide 4a was coupled 
to the amino-hydroxyanthraquinone PEG-like spacer com-
pound 3 (fluorescence quencher), using PyBOP, HOBt and 
DIPEA, to afford a trityl protected rhodamine-anthraqui-
none conjugate intermediate that upon TFA-mediated tri-
tyl deprotection, gave the novel peptide-linked fluorogenic 
rhodamine-anthraquinone conjugate probe 5.
Separately, TFA removal of the trityl group in compound 
4a gave Rho-Pro-Ala-Asn-OH 4b; an authentic sample of 
the predicted fluorescent product from legumain-mediated 
cleavage of fluorogenic substrate probe 5 at the C-terminus 
of its Asn residue.
For fluorescence studies, comparator rhodamine-labelled 
negative control tripeptide, Rho-β-Ala-Ala-Asn-OH 6, in 
which rhodamine-B was attached to the primary amino 
group of a β-Alanine residue (in contrast to the secondary 
amino group of Pro in the equivalent P3 position in probe 
5) was synthesised by analogous SPPS procedures to those 
used for probe 5.
Fluorescence Properties of Rho‑Labelled Tripeptides 
4b and 6; pH Dependence
We have shown previously that oligopeptide substrates, fluo-
rescently labelled with fluorescein derivatives from the xan-
thene class of dyes, can be efficiently activated by the cancer-
associated endoprotease MMP-9 in the microenvironment of 
myeloma (Valckenborgh et al. 2005) however, fluoresceins 
suffer from undesirable decrease in fluorescence intensity 
on lowering the pH (Cook and Le 2006), which makes them 
unsuitable for applications in the acidic environment of the 
lysosomes. To overcome this limitation, in this study, the 
xanthene class of rhodamine-based compounds offered a 
more robust platform for the design of efficient fluorogenic 
substrates of the endoprotease legumain. The fluorescent 
cleavage product expected from the legumain-mediated 
activation of probe 5 was the rhodamine B-labelled, Rho-
Pro-Ala-Asn-OH 4b. An authentic sample of fluorophore 4b 
was synthesised and characterised to determine whether or 
not its photophysical properties would be suitable to facili-
tate continuous reaction monitoring of activation of probe 5 
by legumain. As shown in Fig. 2a, Rho-labelled tripeptide 
4b was strongly fluorescent across the tested pH (3.0–8.0) 
range; thus making it a suitable fluorophore for biological 
studies under physiological conditions, including the highly 
acidic environment of the lysosome and the pH at which the 
lysosomal legumain is catalytically active (Chen et al. 1997).
The importance of the tertiary amide group at the Rho-
Pro junction was underlined by comparing the properties of 
fluorophore 4b with a control peptide 6 in which Rho-β-Ala 
was substituted. As shown in Fig. 2b, compound 6 was mini-
mally fluorescent at pH 3.0–4.0 and barely fluorescent, even 
at fourfold greater concentration than fluorophore 4b, at the 
lysosomal pH range (5.0–6.0) of active legumain, making 
it unsuitable for cell studies and imaging. These observa-
tions were consistent with the known formation of non-
fluorescent spirolactam forms of secondary amide-linked 
rhodamines (Beija et al. 2009). Furthermore, the selection 
of fluorophore 4b as a component of the FRET substrate 
probe 5, was based upon its invariant fluorescence emission 
wavelengths or intensity of emission at the analytical wave-
length (λem 583 nm) with varying pH and corresponding 
constant absorption bands in the visible spectrum (see Sup-
plementary Information Section 5 Fig. S4). The selection 
of the quencher moiety (acceptor) compound 3, in probe 5, 
comprised of a purple 1-amino-substituted-4-hydroxyanth-
raquinone chromophore, was made on the basis of its strong 
visible absorption (see Supplementary Information Section 4 
Fig. S3) spectral overlap with the fluorescence emission of 
fluorophore 4b, fulfilling a fundamental requirement for an 
efficient FRET pair (Sapsford et al. 2006).
Furthermore, the efficient silencing of rhodamine fluo-
rescence in FRET probe 5 is shown over a range of concen-
trations when compared with compound 4b, its legumain-
released cleavage product fluorophore (Fig. 3).
Determination of Relative Fluorescence Quantum 
Yields and Substrate Kinetic Assay
The most widely used, commercially available, fluoro-
genic (non-FRET-based) substrate probe for legumain, 
CBZ-Ala-Ala-Asn-AMC (Km 80 ± 6 μM) (Mathieu et al. 
2002) consists of the fluorogenic chromophore 7-amino-
4-methylcoumarin (AMC) and a legumain-recognised 
peptide. Biological applications of this substrate are lim-
ited because its fluorescence is pH-dependent and it can 
incur interference from other molecules in a biological 
matrix due to its short emission wavelength. Conversely, 
we have shown that the rhodamine B-based fluorophore 4b 
in addition to pH-independent fluorescence, has a higher 
quantum yield, is excited and emits at longer wavelengths 
(Table 1), making it more suitable for biological applica-
tions than several commercially available fluorophores. 
Rhodamine B was used as a reference standard for relative 
fluorescence quantum yield determinations. The fluores-
cence quantum yield of the Rho-Pro-linked fluorophore 
4b (ΦF 0.95) was higher than the Rho-β-Ala-linked ana-
logue 6 (ΦF 0.11) due to the latter adopting ring-closed 
non-fluorescent forms at low pH. The ability to control 
the fluorescent properties of the rhodamine label in fluo-
rophore 4b facilitated the design of probe 5 prompting our 
experiments to evaluate its potential application in pro-
filing protease activity in live cancer cells and lysosome 
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targeting. Legumain substrate probe 5 was shown to have a 
lower Km value (Km ± 1.5 μM) and greater specific activity 
(960 pmol/min/µg) than CBZ-Ala-Ala-Asn-AMC (Mathieu 
et al. 2002).
In Vitro Chemosensitivity
In order for the novel legumain probe 5 to have potential 
future applications in in vivo models, it was important to 
assess its effect on the growth of cancer cells. The cancer 
cell growth inhibitory properties (Table 1) of the legumain 
substrate probe 5 [Rho-Pro-Ala-Asn-PEG-AQ(4-OH)] and 
its legumain mediated cleavage fragments: the quencher 3 
[PEG-AQ(4-OH)] and fluorescent tripeptide 4b (Rho-Pro-
Ala-Asn-OH) were determined by a modification (Plumb 
et al. 1989) of the colourimetric-based MTT assay in PC3 
prostate cancer cells (96 h incubation). (See Supplemen-
tary Information Section 2 Fig. S1 for MTT cytotoxic-
ity assay data). Fluorescent tripeptide reporter 4b was 
non-toxic at all concentrations tested (up to 100 µM) and 
fluorogenic substrate probe 5 had an  IC50 value > 100 µM. 
The amino-hydroxyanthraquinone quencher 3 was also 
poorly cytotoxic  (IC50 23.27 ± 0.04 µM) at the highest 
test concentration. The data indicated that probe 5 (and its 
legumain-induced cleavage products) should be relatively 
non-toxic to the normal cellular environment.
Fig. 2  a Fluorescence spectra 
of compound 4b (Rho-Pro-Ala-
Asn-OH; 10 µM) in Mcllvaine 
buffer; pH range 3.0–8.0, λex 
562 nm, λem 583 nm. b Fluo-
rescence spectra of compound 
6 (Rho-β-Ala-Ala-Asn-OH; 
40 µM) in Mcllvaine buffer pH 
range 3.0–8.0, λex 562 nm, λem 
583 nm
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Fig. 3  Comparison of variation in Relative Fluorescence Intensity 
with concentration for probe 5 and fluorophore tripeptide 4b (Rho-
Pro-Ala-Asn-OH), λem 583 nm; (n = 3)
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Activation of Probe 5 by Recombinant Human Legu‑
main In Vitro
To assess the ability of the fluorogenic FRET probe 5 
[(Rho-Pro-Ala-Asn-PEG-AQ(4-OH)] to act as a legumain 
substrate, an in vitro fluorimetric assay was developed 
using rh-legumain at 37 °C in MES assay buffer (pH 5.0). 
Incubation of probe 5 (10 µM) with rh-legumain (0.40 ng/
μL) at 37 °C for 2 h, afforded a time-dependent increase in 
relative fluorescence intensity, monitored at the emission 
wavelength (λem 583 nm) of rhodamine-labelled peptide 
4b, as shown in (Fig. 4). Incubation of probe 5 in assay 
buffer in the absence of enzyme resulted in no fluorescence 
release. Furthermore, pre-incubation of rh-legumain with the 
cysteine protease inhibitor iodoacetamide (1 mM; 15 min) 
completely abolished fluorescence release. The designed 
probe 5 was determined to be an efficient FRET substrate 
affording good restoration of fluorescence upon activation 
by legumain under acidic pH conditions that mimic those 
typically observed in lysosomes.
Subcellular Localisation of Probe 5 to Lysosomes 
of Live PC3 Prostate Cancer Cells
The acidity of the lysosome (pH 4.5–5.5) is critical to the 
optimal activity of legumain. Confocal imaging was per-
formed to analyse the cellular uptake and localisation of 
legumain probe 5 in live PC-3 prostate cancer cells in the 
presence of commercially available, lysosomal-targeting 
LysoTracker Green DND 26 probe. Legumain-expressing 
(Ohno et al. 2013), PC-3 cells were treated with a co-stain 
solution of LysoTracker Green DND 26 (60 nM) and probe 
5 (1 µM). Co-stain was applied to the cell culture medium 
and incubated at 37 °C for 30 min prior to imaging. Fig-
ure 5a shows the cellular uptake of probe 5 in PC-3 cells 
at imaging time points 0, 30, 60 and 120 min. Legumain 
substrate probe 5 was detected in the lysosomes, but not in 
the nucleus. Probe 5 showed a punctate staining pattern near 
the perinuclear regions of the live cells (panels E, H and K) 
and clear colocalisation with stained lysosomes (panels F, I 
and L). The cellular uptake of probe 5 was facilitated by its 
cationic lipophilic character (Log D: + 1.78 ± 0.29).
The colocalization of probe 5 with LysoTracker Green 
DND 26, is consistent with reports that rhodamine-based 
compounds prefer the acidic environment of lysosomes (Yu 
et al. 2015) over other organelles (probe 5 did not colocal-
ize with MitoTracker Green FM-treated PC-3 cells; (data 
available in Supplementary Information Section 8 Fig. S7). 
Probe 5 was observed in the lysosomes within 30 min of 
treatment confirming that it can reach the environment of 
its intended activating enzyme; it is well established that the 
target protease legumain is overexpressed within the acidic 
Table 1  Summary of maximal 
absorption (λabs) and emission 
wavelengths (λem), molar 
extinction coefficients, relative 
fluorescence quantum yields 
(ΦF), distribution coefficients 
and cytotoxicity data
a Quantum yields for 4b and 6 were obtained by the comparison of the integrated area of the emission spec-
trum of the samples with Rhodamine B in absolute ethanol (pH: 5); for AMC data was obtained from the 
literature (Fischer et al. 1995)
b Determined experimentally in octanol/PBS using the shake flask method
c Concentrations of compound to reduce cell viability by 50%, determined in 96  h drug incubations by 
MTT assay (Plumb et al. 1989). Values are means of three independent experiments performed in triplicate 
with ± being the standard error of the mean
d Km ± 1.5 μM for 5 (activated by recombinant human legumain)
Compound λab (nm) ε (L/mol/cm) λem (nm) ΦFa Log  Db IC50 (μM)c
3 553 1.43 × 104 − 0.67 ± 0.19 23.27 ± 0.04
5d 560 6.39 × 104 1.78 ± 0.29 > 100
4b 556 5.89 × 104 583 0.95 − 0.59 ± 0.11 > 100
6 552 0.24 × 104 580 0.11 n.d. n.d.
AMC 352 1.70 × 104 429 0.51 n.d. n.d.
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Fig. 4  Variation in relative fluorescence intensity released with time 
for probe 5 (10  µM) upon incubation with rh-legumain (0.40  ng/
μL) in legumain assay buffer (pH 5.0) with (red dots) and without 
(green dots) pre-incubation of legumain with iodoacetamide (1 mM, 
15  min), λex 544  nm, λem 583  nm; enzyme-free probe 5 only (blue 
dots) (n = 3)
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Fig. 5  a Confocal microscopy 
live cell images of PC-3 cells 
treated with probe 5 (1 μM) 
for up to 2 h (scale bar 20 μm). 
Lysosomes were stained with 
LysoTracker Green DND 26 
(60 nM). Areas where probe 
5 and lysosomes colocalize 
appear as yellow. Images were 
captured at 63 x magnification. 
b Degree of colocalization of 
probe 5 and LysoTracker Green 
DND 26
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environment of the lysosomes (Halfon et al. 1998; Kembhavi 
et al. 1993). Pearson’s correlation coefficient and Mander’s 
overlap coefficient were used for quantifying the degree of 
co-localisation of probe 5 and LysoTracker Green DND 26 
(Fig. 5b), showing good agreement between methods across 
the 2 h incubation.
Prostate Cancer Fresh‑Frozen Tissue Studies
Given the limitations of serum PSA levels as a biomarker, 
histological evaluation of prostate core biopsies and resec-
tion samples is often more reliable, but the use of a histo-
logical diagnosis only as a sole marker, in the decision of 
treatment and prognosis, may not be appropriate, as it is not 
always predictive of which lesion will remain dormant for 
a substantial number of years, and which one will become 
aggressive in a short period of time. This emphasises the 
need for additional assays and technologies that could be 
used as diagnostic and predictive assays of prostate cancer 
development and which could help inform or advance fur-
ther therapies.
To this end, one of our principal objectives was to inves-
tigate whether or not the designed fluorogenic FRET sub-
strate probe for legumain 5 would be activated by tissue 
homogenates from prostate tissue samples; and whether or 
not this could be attributed to legumain activity, mindful 
that other proteases in tissue may interact with the probe. In 
prostate cancer patients all tissue specimens derived either 
from biopsy or prostatectomy are of diagnostic value. There-
fore, it is often difficult to obtain material dedicated purely 
for research activities. Since for our assay we did not require 
to maintain tissue morphology; rather, to see what section 
of tissue was put into homogenates, we therefore opted to 
test our idea on trimming surplus material that remained 
from diagnostic frozen sections for two areas: benign and 
malignant. We selected the first specimen (PO1) with the 
least amount of tumour in the gland (< 1%), where the frozen 
section was taken from a clearly defined benign area, and 
the second specimen (PO2), where the tumour was clearly 
identified on macroscopic assessment and the frozen section 
was taken from this malignant area.
As a prelude to incubating the legumain substrate 
probe 5 with prostate tissue homogenates, it was consid-
ered important to prepare a negative control analogue 7 
which lacked the cleavage hotspot for legumain. This was 
achieved by substituting the Asn residue by Ala, to afford 
the sequence Rho-Pro-Ala-Ala-PEG-AQ(4-OH) in 7. As 
shown in (Fig. 6), probe 5 was shown to be an efficiently-
activated substrate whereas compound 7 was unaffected by 
rh-legumain. It was recognised that tissue can be expected 
to possess protease activity other than that due to legu-
main; however, in the given substrates the N-terminus 
is protected from possible aminoprotease cleavage by 
the rhodamine capping group and the C-terminus is pro-
tected from carboxypeptidase action by the anthraquinone 
quencher capping group, conferring resistance to enzyme-
mediated reactions at the termini. Potentially, other endo-
proteases may cleave the control peptide 7 and/or probe 
5 and one identifiable class may be the cathepsin family 
of cysteine proteases that co-occur in the lysosomes, and 
which catalyse proteolysis of a wide range of peptide and 
protein substrates (Łęgowska et al. 2014). In order to pro-
vide further strong evidence that probe 5 is selectively 
cleaved by active legumain, incubations of probe 5 were 
conducted with recombinant cathepsin L, known to be 
secreted by lysosomal exocytosis by prostate cancer cells 
(Sudhan and Siemann 2013). Substrate 5 was not activated 
by cathepsin L (data available in Supplementary Informa-
tion Section 11 Fig. S14).
Prostate Cancer Fresh‑Frozen Tissue Patient‑Derived 
Samples: Probe Activation Studies
Prostate tissue samples were homogenised and the result-
ing supernatants were treated with probe 5 in legumain 
MES assay buffer at pH 5.0. Representative data from tis-
sue samples from two patients (PO1 and PO2) are pre-
sented in Fig. 7a and b, respectively.
In each example, a substantial and sustained increase in 
relative fluorescence intensity was observed upon incuba-
tion with the designed legumain substrate probe 5, whereas 
no increase occurred with the control non-legumain sub-
strate 7 (wherein the critical Asn residue and cleavage 
‘hotspot’ had been replaced by Ala).
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Fig. 6  Variation in relative fluorescence intensity with time upon 
incubation of Rho-Pro-Ala-Asn-PEG-AQ(4-OH) (probe 5; 10  µM) 
and Rho-Pro-Ala-Ala-PEG-AQ(4-OH) (control peptide 7; 10  µM) 
with rh-legumain (0.40 ng/μL) in legumain assay buffer (pH 5.0) λex 
544 nm, λem 583 nm (n = 3)
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Furthermore, in each case, the fluorescence release due 
to activation of probe 5 was prevented by pre-incubation 
with the legumain protease inhibitor iodoacetamide.
The tissue sample data closely mirrors that obtained for 
the activation of probe 5 by recombinant human legumain 
and is entirely consistent with the predicted response of a 
legumain-mediated activation.
A large increase in fluorescence upon activation of 
probe 5 was observed in the case of the malignant tumour 
sample (PO2) that was abrogated by the legumain inhibitor 
iodoacetamide. However, for the sample (PO1) classified 
benign by histological examination, a notable fluorescence 
release was obtained and similarly abrogated. Further 
studies are required to assess whether probe 5, as a poten-
tial complementary tool, may be able to discern low level 
malignancy compared to other methods, should expression 
of legumain prove to be a reliable and validated biomarker.
Conclusions
The fluorogenic probe 5 is an efficient FRET peptide substrate 
for cancer associated legumain (accessible by a simple and 
inexpensive synthesis) that affords strong restoration of fluo-
rescence during incubation with rh-legumain. An advantage 
of probe 5 is that unlike previously reported substrates, the 
fluorescence intensity of the liberated fluorophore 4b (high 
fluorescence quantum yield ΦF 0.95) is unaltered over a wide 
range of pH (3–8), an important factor given the acidic pH 
environment of many solid tumours, making it an effective and 
sensitive reporter fluorophore. Furthermore, it is shown that 
probe 5 is taken up by live legumain-expressing PC3 prostate 
cancer cells and transported to the lysosomes where putative 
biomarker legumain is located. In preliminary investigations, 
the probe 5 approach in frozen tissue samples has afforded 
some promising results in correlation with reported histologi-
cal findings, as we have seen a large increase in fluorescence 
intensity in the sample with foci of prostatic adenocarcinoma 
compared to the sample with benign prostate glands. In future, 
more studies using probe 5 need to be done in prostate tis-
sue specimens (ongoing) to validate its application as a new 
supportive assay; these experiments will be necessary also to 
interrogate correlation of results with imaging and PSA levels.
Probe 5 represents a new viable biochemical tool for prob-
ing the activity of legumain in vitro with the potential to be 
used ex vivo to characterise prostate biopsy samples in a diag-
nostic setting in the pathology laboratory, to supplement cur-
rent tumour characterisation.
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Fig. 7  a Variation in relative fluorescence intensity released with time 
for probe 5 (10 µM) with and without pre-incubation with iodoacet-
amide (1  mM, 15  min), and control peptide 7 (10  µM), upon incu-
bation with tissue homogenate from prostate benign* tissue sample 
(PO1); λex 544  nm, λem 583  nm, (n = 3); *classified by histological 
examination. b Variation in relative fluorescence intensity released 
with time for probe 5 (10 µM) with and without pre-incubation with 
iodoacetamide (1 mM, 15 min), and control peptide 7 (10 µM), upon 
incubation with tissue homogenate from prostate cancer tissue sample 
(PO2); λex 544 nm, λem 583 nm, (n = 3)
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